secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2026-03-06T23:59:59+00:00
Accession:  0001213900-26-024336
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals FY2025 net loss $8M, cash $5.9M; advancing AD04 toward Phase 3
--------------------------------------------------------------------------------

- Net loss of $8.0M in FY2025 vs $13.2M in FY2024, driven by lower R&D and 2024 one-time $4.5M inducement expense.
- Cash and cash equivalents $5.9M as of Dec 31, 2025, up from $3.8M; expected to fund operations into H2 2026.
- Entered collaboration framework with Molteni for European AD04 commercialization; potential value ~$60M if successful.
- Regained Nasdaq minimum bid price compliance on Feb 23, 2026; matter now closed.
- Completed EOP2 meeting with FDA; secured U.S. manufacturing partners Cambrex and Thermo Fisher for late-stage development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026024336/0001213900-26-024336-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390026024336/ea0280282-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-024336

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer